#NephJC
The #TenPostNephJC on REACT injections in DKD is live !!
Missed the chat?
Need a short recap of the study ?

We’ve got you covered !! 😃

1/10
Welcome to #TenPostNephJC
Can we move beyond slowing CKD → to actually repairing the kidney?
Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.

1/10 Last #NephJC we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN #TenPostNephJC
Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit.
www.nejm.org/doi/full/10....

1/10

Last #NephJC we discussed dialysis frequency in AKI-D #TenPostNephJC

We sought to answer an age-old question: Is less is really more? Or less is just simply what it is….less?

pubmed.ncbi.nlm.nih.gov/41201895/

1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed the PISCES study 🐟 on the role of fish oil on cardiovascular events in hemodialysis patients. This study was presented at Kidney Week with simultaneous publication, and was as unexpected as a shark attack🦈.

1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....

1/10
Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC .
Read the article 👇
pubmed.ncbi.nlm.nih....

1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed tolerance induction in HLA matched 🫘 transplants with donor Hematopoietic stem cells (MDR-101).
Missed the Chimeri-chat? No worries - We’re quite “tolerant” to those who missed their IS(Informative Session)!

pubmed.ncbi.nlm.nih.gov/39922283/

1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed about AHA/ACC 2025 Hypertension guidelines: PREVENT, Detect, Treat
Didn’t catch the pulse of this one? No worries we’ll help you pressure check the 2025 AHA Hypertension Guidelines. ❤ #AHA2025
www.ahajournals.org/doi/10.1161/...

Last #NephJC we discussed the ACHIEVE trial: spironolactone in ESRD patients to decrease cardiovascular outcomes. #TenPostNephJC
#NephSky
Read the article 👇
pubmed.ncbi.nlm.nih.gov/40818850/

1/10
Last #NephJC we discussed HiLo: Hi vs Lo phos targets in HD patients #TenPostNephJC

Can restricted diets & loading patients full of phos binders be filed under “Things We Do For No Reason,” or do we finally have proof these measures save lives?

pubmed.ncbi.nlm.nih.gov/40638247/

Higher versus Lower Phosphate Targets for Patients Undergoing In-Center Hemodialysis: A Randomized Controlled Trial - PubMed Insufficient enrollment and inadequate phosphate separation between groups preclude inferences about the effects of phosphate targets on clinical outcomes.

10/ Final thoughts
👉eGFRdiff is still an enigma but may have prognostic implications
👉eGFRdiff is just based on estimates (caveat emptor)

➡️Up next: HiLo & phos control in ESKD pubmed.ncbi.nlm.nih.gov/40638247

#TenPostNephJC by @thekidneywhisperer.bsky.social

Join us www.nephjc.com/

Last #NephJC we discussed the significance and causes of eGFRdiff, the difference between eGFR creatinine and cystatin C (eGFRdiff= eGFRcys-eGFRcr)

#TenPostNephJC #NephSky

Read the article 👇
pubmed.ncbi.nlm.nih.gov/40373998/

Complex Etiologies of the Discordance Between Cystatin C- and Creatinine-Based Estimated GFR and Its Adverse Associations: Findings From the CRIC Study - PubMed The difference between estimated glomerular filtration rates (eGFR_diff) using serum creatinine and cystatin C (eGFR_cys-eGFR_cr) has been repeatedly associated with adve...

👋 #TenPostNephJC 🧵by @salinesolut.bsky.social

➡️Up next, July 22, Complex Etiologies of Discordance between Cys-C and Crea eGFR @ajkd.bsky.social

pubmed.ncbi.nlm.nih.gov/40373998/

1/10
Last #NephJC we discussed the combination therapy of empagliflozin and finerenone 💊 #TenPostNephJC

🌵From a therapeutic dessert to a flood of options in diabetic kidney disease (DKD) - what is the best timing to keep the kidneys afloat

1/10
Last #NephJC we discussed the use of nudges 🫵 #TenPostNephJC
In this study e-nudges (email) were sent to general practitioners (GPs) & patients to see if the uptake of goal-directed medical therapy (GDMT) in diabetic CKD could be increased.
Read the article 👇
pubmed.ncbi.nlm.nih.gov/40481660/

1/10
Last #NephJC we discussed tacrolimus (TAC) versus mycophenolate mofetil (MMF) for the treatment of pediatric nephrotic syndrome. A first👶to👶immunosuppression study for SSNS in kids #TenPostNephJC .
Read the articles 👇
pmc.ncbi.nlm.nih.gov/articles/PMC...

1/10
Last #NephJC we discussed the role of prophylactic DDAVP for preventing post kidney biopsy (KBx) bleed #TenPostNephJC .
The articles 👇
@kireports.bsky.social @asnpublications.bsky.social @jeyakumarmeyyappan.bsky.social

www.kireports.org/article/S246...

pubmed.ncbi.nlm.nih.gov/40067357/

Aldosterone month for #NephJC

Catch up with the last one tackling adrenal vein sampling. Should you withdraw the MRA and risk rocking the boat, or are you really safe in doing so?

#TenPostNephJC

1/10
Last #NephJC we continued our Aldo streak as we discussed mineralocorticoid antagonist (MRA) withdrawal before ✅aldosterone renin ratio (ARR) & adrenal vein sampling (AVS) #NephSky #MedSky
#TenPostNephJC makes this #Endosky oriented topic easy.
pubmed.ncbi.nlm.nih.gov/39660429/

1/10
Were u unable to attend last #Nephjc ..still reeling from the jetlag of #ISNWCN? ✈️ #NephSky #MedSky
No worries, the #TenPostNephJC will help you unravel the enigmas of Primary hyperaldosteronism!
pubmed.ncbi.nlm.nih.gov/39660429/

1/10
Still not over the holiday season? 🎄 #NephSky #MedSky
Did u know that December 2024 saw the first ever #NephJC exclusively hosted on #Bluesky🥂 (as we said goodbye to ✖️!)
Bringing to you the #TenPostNephJC to help you ACE the management of advanced CKD!
pubmed.ncbi.nlm.nih.gov/38950402

Image text: #TenPostNephJC 1. Intro 2. So I didn’t join – what was the study? 3. one post methods 4. one post results 5. A figure paints a 1000 words 6. Give me something clever to say 7. Was the consensus in the chat? 8. Quote of the fortnight! 9. I want more info 10 Final thoughts

Did you miss last week’s #NephJC chat? Still lost over ✖️ or 🦋?
No worries, the #TenPostNephJC will get you caught-up on BPROAD -- Intensive #BloodPressure Control in Patients with Type 2 #Diabetes
#NephSky #MedSky 1/10 🧵

#TenTweetNephJC 1. Intro 2. So I didn't join - what was the study? 3. 1 tweet methods 4. 1 tweet results 5. A figure paints a 1000 words 6. Give me something clever to say 7. Was there a consensus in the chats? 8. Quote of the fortnight! 9. I want more info 10. Final thoughts #NephJC Logo in the bottom right corner

1/10
Too confused which #NephJC chat to attend ✖️ or 🦋?
#TenPostNephJC will keep u updated about the best of both worlds!
Last chat we discussed the #ADAPT trial from
#KidneyInternational

🎲RCT of 2K vs 3Kdialysate/SZC
📖Read full text 👇 #NephSky
doi.org/10.1016/j.ki...

1/10
Did you miss last week’s #NephJC chat?
Too busy fretting over politics?
No worries, this #TenPostNephJC will get you all caught-up on Long-term Effects of #Empagliflozin in patients with #CKD
#NephSky #SkyNeph #MedSky

Welcome to #TenTweetNephJC
#TenPostNephJC
✳️10 posts to catch you up on latest #NephJC ✳️
🤢 Nausea is a very common problem for patients on HD 🤢
Unfortunately, the pharmacopeia for n/v may carry risks of Torsades de Pointes & sudden cardiac death (SCD) 👉 pubmed.ncbi.nlm.nih.gov/38409683/
#Kidneywk

#TenPostNephJC 1. Intro 2. So I didn’t join, what was the study? 3. 1 tweet methods 4. 1 tweet results 5. A figure paints 1000 words. 6. Give me something clever to repeat. 7. Was there consensus in the chats? 8. Quote of the fortnight! 9. I want more info. 10. Final thoughts

1/10 Welcome to #TenTweetNephJC
#TenPostNephJC
✳️ 10 posts to catch you up on the latest #NephJC ✳️
Couple of weeks back we discussed FINE♥️ (www.nature.com/articles/s41...)

1. Intro 2. So I didn’t join, what was the study? 3. 1 tweet methods 4. 1 tweet results 5. A figure paints 1000 words. 6. Give me something clever to repeat. 7. Was there consensus in the chats? 8. Quote of the fortnight! 9. I want more info. 10. Final thoughts

1/10 Welcome to #TenTweetNephJC
#TenPostNephJC
Have you heard of the new kid on the block for Antibody mediated rejection?Felzartamab!
We reviewed data from the recent phase II trial of this anti CD38 monoclonal antibody 🆕 in #NEJM

www.nejm.org/doi/full/10.... #NephJC

Welcome to #TenTweetNephJC
#TenPostNephJC
✳️ #NephJC catch-up ✳️
What is the best target systolic BP in patients w/ high-risk CV comorbidities? We reviewed ESPRIT 👻 , in Lancet, comparing SBP 120 vs 140 mmHg in Chinese patients w/ vascular risks, DM & stroke. pumbmed.ncbi.nlm.nih.gov/38945140/